Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 3

2510 - Assessment Quality of Life with Hand-Foot Syndrome Induced by Apatinib Combined with Anti-PD-1 Therapy in NSCLC


30 Sep 2019


Poster Display session 3


Qi Jiang


Annals of Oncology (2019) 30 (suppl_5): v836-v845. 10.1093/annonc/mdz276


Q. Jiang, P. Shen

Author affiliations

  • Medical Oncology, 1st Affiliated Hospital of Zhejiang University School of Medicine, 310003 - Hangzhou/CN


Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 2510


Hand-foot syndrome (HFS) related to new targeted therapies is a common cutaneous toxicity, with potentially serious impacts on the patient QoL. Previous reports indicate that the incidence of HFS was about 30% in apatinib monotherapy for NSCLC. HFS was also reported to be associated with immunotherapy. We conducted a phase II clinical trial on apatinib combined with anti-PD-1 antibody SHR-1210 for advanced NSCLC (No. CTR20170090). Whether the combined therapy leads to a dramatic increase in the incidence of HFS remains uncertain. There are a variety of scales to evaluate the patients’ QoL, but the specific scale for patients with HFS needs further verification.


Multiply questionnaires including the HFS-specific QoL questionnaire (HFS-14), Dermatology Life Quality Index (DLQI), Skindex-16 and short-form 12 health-related questionnaire (SF-12) were developed to measure the effect of HFS on daily activities. The HFS clinical grade was based on NCI-CTCAE, v3.0.


The validation study included 26 patients, of 21 (80%) developed HFS of varying grades, with 8 (31%) of grade 1, 7 (27%) of grade 2 and 6 (23%) of grade 3. 52% of patients declared involving one limb, and the rest patients developed HFS in both the hands and feet. The mean time to occurring HFS was 30 ± 64 days. In patients with various grades of HFS, the mean HFS-14 and DLQI scores were significantly higher with higher HFS grades, whereas the Skindex-16 and SF-12 scores did not differ. Four kinds of scales analysis also showed significant differences according to the degree of limb involvement, where the scores were significantly higher in patients having both hands and feet severely involved than in those having severe involvement of either only the hands or feet. When in patients with grade 2 HFS, the HFS-14 score was significantly higher in patients involving both the hands and the feet than in patients having only the hands or the feet severely affected; while Skindex-16, DLQI and SF-12 scores have no difference between these two groups.


The incidence of HFS induced by the treatment of anti-PD-1 antibody SHR-1210 combined with apatinib is extremely high. HFS-14 may serve as a more sensitive and valuable tool for early measuring HFS-related QoL impairment.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.


Has not received any funding.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.